Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lactoferrin protects neonatal rats from gut-related systemic infection
Autore:
Edde, L; Hipolito, RB; Hwang, FFY; Headon, DR; Shalwitz, RA; Sherman, MP;
Indirizzi:
Univ Calif Davis, Div Neonatol, Dept Pediat, Davis, CA 95616 USA Univ Calif Davis Davis CA USA 95616 tol, Dept Pediat, Davis, CA 95616 USA Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA Univ Arizona Tucson AZ USA 85724 izona, Dept Pediat, Tucson, AZ 85724 USA Agennix Inc, Houston, TX 77046 USA Agennix Inc Houston TX USA 77046Agennix Inc, Houston, TX 77046 USA Abbott Labs, Ross Prod Div, Columbus, OH 43215 USA Abbott Labs Columbus OH USA 43215 , Ross Prod Div, Columbus, OH 43215 USA Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 , Dept Pediat, Houston, TX 77030 USA
Titolo Testata:
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
fascicolo: 5, volume: 281, anno: 2001,
pagine: G1140 - G1150
SICI:
0193-1857(200111)281:5<G1140:LPNRFG>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTESTINAL EPITHELIAL-CELLS; HUMAN-MILK; BACTERIAL TRANSLOCATION; NECROTIZING ENTEROCOLITIS; NITRIC-OXIDE; ESCHERICHIA-COLI; GASTROINTESTINAL-TRACT; PROTEOLYTIC CLEAVAGE; DEFENSIN EXPRESSION; BOVINE LACTOFERRIN;
Keywords:
bacteremia; Escherichia coli; disease severity score; human lysozyme; macrophage-related priming or activation; recombinant human lactoferrin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Sherman, MP Univ Calif Davis, Div Neonatol, Dept Pediat, TB 193, Davis, CA95616 USA Univ Calif Davis TB 193 Davis CA USA 95616 Davis, CA 95616 USA
Citazione:
L. Edde et al., "Lactoferrin protects neonatal rats from gut-related systemic infection", AM J P-GAST, 281(5), 2001, pp. G1140-G1150

Abstract

Lactoferrin is a milk protein that reportedly protects infants from gut-related, systemic infection. Proof for this concept is limited and was addressed during in vivo and in vitro studies. Neonatal rats pretreated orally with recombinant human lactoferrin (rhLF) had less bacteremia and lower disease severity scores (P< 0.001) after intestinal infection with Escherichia coli. Control animals had 1,000-fold more colony-forming units of E. coli per milliliter of blood than treated animals (P, 0.001). Liver cultures from control animals had a twofold increase in bacterial counts compared with cultures from rh-LF-treated pups (P< 0.02). Oral therapy with rh-LF + FeSO4 did not alter the protective effect. In vitro studies confirmed that rh-LF interacted with the infecting bacterium and rat macrophages. An in vitro assay showed that rh-LF did not kill E. coli, but a combination of rh-LF + lysozyme was microbicidal. In vitro studies showed that rat macrophages released escalating amounts of nitric oxide and tumor necrosis factor-alpha when stimulated with increasing concentrations of rh-LF. The in vitro studies suggest that rh-LF may act with other "natural peptide antibiotics" or may prime macrophages to kill E. coli in vivo.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 05:19:38